Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AMPH 
Amphastar P (AMPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: AMPH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $32.67
1 Year Target Price $32.67
| 2 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 4.87% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.41B USD | Price to earnings Ratio 11.33 | 1Y Target Price 32.67 |
Price to earnings Ratio 11.33 | 1Y Target Price 32.67 | ||
Volume (30-day avg) 6 | Beta 0.76 | 52 Weeks Range 20.39 - 53.95 | Updated Date 08/29/2025 |
52 Weeks Range 20.39 - 53.95 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.67 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate 0.74 | Actual 0.85 |
Profitability
Profit Margin 18.64% | Operating Margin (TTM) 24.19% |
Management Effectiveness
Return on Assets (TTM) 7.31% | Return on Equity (TTM) 18.32% |
Valuation
Trailing PE 11.33 | Forward PE - | Enterprise Value 1841380897 | Price to Sales(TTM) 1.95 |
Enterprise Value 1841380897 | Price to Sales(TTM) 1.95 | ||
Enterprise Value to Revenue 2.55 | Enterprise Value to EBITDA 7.42 | Shares Outstanding 46495100 | Shares Floating 35344628 |
Shares Outstanding 46495100 | Shares Floating 35344628 | ||
Percent Insiders 24.02 | Percent Institutions 71.81 |
Upturn AI SWOT
Amphastar P
Company Overview
History and Background
Amphastar Pharmaceuticals, Inc. was founded in 1996. It focuses on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. Amphastar initially specialized in manufacturing and selling generic versions of existing drugs but later expanded into proprietary products.
Core Business Areas
- Finished Pharmaceutical Products: Develops, manufactures, and markets generic and proprietary injectable and inhalation products, including anti-coagulants, anti-inflammatories and complex generics.
- API (Active Pharmaceutical Ingredients): Manufactures and sells APIs to other pharmaceutical companies.
- Animal Health: Develops, manufactures, and markets generic injectable pharmaceutical products for veterinary applications.
Leadership and Structure
The key leadership includes Dr. Jack Zhang (Chairman and CEO) and William Peters (CFO). The company operates with a functional organizational structure with departments focusing on R&D, Manufacturing, Sales & Marketing, and Finance.
Top Products and Market Share
Key Offerings
- Enoxaparin Sodium Injection: A generic version of Lovenox, an anticoagulant used to prevent and treat blood clots. Market share is significant within the generic enoxaparin market. Competitors include Sandoz, Mylan (now Viatris), and Teva Pharmaceutical.
- Epinephrine: Epinephrine products treat allergic reactions. Competitors include Mylan (Viatris) and Teva Pharmaceuticals.
- Primates: Provides Primates for Research purposes. Market share in this field is one of the leaders with limited competitiors. This makes up a small percentage of the total revenue.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly regulated and competitive. The generic injectables market is driven by patent expirations and cost-containment pressures. Inhalation segment is driven by increasing rates of respiratory diseases such as Asthma.
Positioning
Amphastar is positioned as a developer and manufacturer of generic and proprietary injectable and inhalation products. The company competes on price and supply reliability.
Total Addressable Market (TAM)
The TAM for generic injectables and inhalation products is estimated to be in the billions of dollars annually. Amphastar captures a portion of this TAM, focusing on niche markets and complex generics.
Upturn SWOT Analysis
Strengths
- Specialized in complex generics
- Vertical integration with API manufacturing
- Strong R&D capabilities
- Established relationships with distributors
- Experienced Management Team
Weaknesses
- Reliance on a limited number of key products
- Exposure to regulatory risks
- Competition from larger pharmaceutical companies
- Fluctuations in API Costs
- Dependence on Third Party Vendors
Opportunities
- Expansion into new therapeutic areas
- Strategic acquisitions
- Growing demand for generic injectables
- Development of biosimilars
- New product launch
Threats
- Increased competition
- Price erosion
- Regulatory changes
- Patent challenges
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- VTRS
- TEVA
- Sandoz (Novartis)
Competitive Landscape
Amphastar's competitive advantage lies in its specialized focus and vertical integration. However, it faces competition from larger pharmaceutical companies with broader product portfolios and greater resources.
Major Acquisitions
International Medication Systems
- Year: 2016
- Acquisition Price (USD millions): 600
- Strategic Rationale: Expanded Amphastar's portfolio of injectable products and strengthened its presence in the institutional market.
Growth Trajectory and Initiatives
Historical Growth: Amphastar's growth has been driven by successful product launches, strategic acquisitions, and increasing demand for generic injectables.
Future Projections: Future growth projections will depend on analyst estimates. Factors to consider include new product approvals, market penetration, and competitive landscape.
Recent Initiatives: Recent initiatives may include new product development programs, acquisitions of other companies, partnerships, and facility expansions.
Summary
Amphastar is a pharmaceutical company specializing in injectable and inhalation products, demonstrating strength in complex generics and vertical integration. Its reliance on limited key products and exposure to regulatory risks are key weaknesses. Strategic acquisitions and expanding into new therapeutic areas presents significant growth opportunities. Increased competition and price erosion pose substantial threats, highlighting the need for continuous innovation and diversification.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Amphastar Pharmaceuticals Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Industry Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Invest at your own risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Amphastar P
Exchange NASDAQ | Headquaters Rancho Cucamonga, CA, United States | ||
IPO Launch date 2014-06-25 | Co-Founder, President, CEO, Chief Scientific Officer & Director Dr. Yongfeng Zhang Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 2028 | Website https://www.amphastar.com |
Full time employees 2028 | Website https://www.amphastar.com | ||
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging, as well as Albuterol Sulfate inhalation aerosol. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.